| 講題 | 主講人 | |
|---|---|---|
| ※研討會內容著作權屬於講者，請遵守著作財產權法規，未經同意不得重製、利用或散佈。 | ||
| 08:50– 09:00 |
Opening Remarks | Dr. Jen-Hsiang Chuang 莊人祥 常務次長 Ministry of Health and Welfare, Taiwan |
| Keynote Speech 1 | ||
| 09:00– 09:40 |
Cancer Genomics and Cancer Prevention: A Propitious Marriage? |
Dr. David Nicholas Church Precision Oncology for Nuffield Department of Medicine, University of Oxford, U.K. |
| Keynote Speech 2 | ||
| 09:40– 10:20 |
Epigenetic Impact of Truncal Mutations in Clear Cell Renal Cell Carcinoma |
Dr. Bin Tean Teh 鄭敏展 教授 National Cancer Centre Singapore, Singapore |
| Session 1: Precision Screening | ||
| 10:40– 11:05 |
Towards Elimination of Helicobacter Pylori for Gastric Cancer Prevention: Taiwan Experience | Dr. Ming-Shiang Wu 吳明賢 院長 College of Medicine, National Taiwan University, Taiwan |
| 11:05– 11:30 |
Precision Colorectal Cancer Prevention – The Road Ahead | Dr. Han-Mo Chiu 邱瀚模 主任 Health Management Center, National Taiwan University Hospital, Taiwan |
| 11:30– 11:55 |
Lung Cancer Screening in Asia | Dr. Pan-Chyr Yang 楊泮池 院長 Young-Lin Institute of Health, National Taiwan University, Taiwan |
| Poster Discussion and Media Interview | ||
| 11:55– 12:30 |
Selected Poster Oral Presentation Discussion and Media Interview |
Dr. Hsiu-Ju Yen 顏秀如 主任 Dr. Jang-Ming Lee 李章銘 教授 Dr. Ming-Shiang Wu 吳明賢 院長 Dr. Pan-Chyr Yang 楊泮池 院士 |
| 講題 | 主講人 | |
|---|---|---|
| Keynote Speech 3 | ||
| 13:40– 14:20 |
Tumor-Infiltrating Lymphocytes: New Insights into Cancer Immunity | Dr. Yosuke Togashi 冨樫 庸介 教授 Department of Tumor Microenvironment, Dentistry and Pharmaceutical Sciences, Graduate School of Medicine, Okayama University, Japan |
| Session 2: Bioinformatics and Cancer Genomics | ||
| 14:20– 14:45 |
Integrating Precision Medicine into the Management of Gastrointestinal Cancers | Dr. Yung-Yeh Su 蘇勇曄 助研究員級主治醫師 National Institute of Cancer Research, National Health Research Institutes, Taiwan |
| 14:45– 15:10 |
Mechanistic Insights into GBE1-Driven Metabolic Reprogramming in Colorectal Cancer | Dr. Fang-Chi Hsu 許芳齊 研究員 Sino-American Cancer Foundation, U.S.A. |
| 15:10– 15:35 |
A Taiwanese Registry-Based Cohort Study of Urological Cancer Revealed a Regionally Enriched Mutational Signature in Upper Tract Urothelial Carcinoma | Dr. Kwang-Yu Chang 張光裕 副研究員級主治醫師 National Institute of Cancer Research, National Health Research Institutes, Taiwan |
| Session 3: From Undruggable to Druggable-Ras pathway | ||
| 15:55– 16:15 |
A Historical Narrative on the Genetic Basis of Cancer | Dr. Chiaho Shih 施嘉和 教授 Kaohsiung Medical University, Taiwan |
| 16:15– 16:35 |
Targeting KRAS Mutations in Cancer: Medicinal Chemistry Strategies and Insights | Dr. Hsing-Pang Hsieh 謝興邦 所長 Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Taiwan |
| 16:35– 16:55 |
ADAM9 Inhibition Promotes KRAS Degradation in Pancreatic Cancer Treatment | Dr. Yuh-Pyng Sher 佘玉萍 所長 Institute of Biochemistry and Molecular Biology, China Medical University, Taiwan |
| 16:55– 17:15 |
RAS Drug Clinical Development | Dr. Chia-Chi Lin 林家齊 所長 Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taiwan |
| 17:15– 17:25 |
Closing Remarks | Dr. Huey-Kang Sytwu 司徒惠康 院長 National Health Research Institutes, Taiwan |